NEW YORK (GenomeWeb) – Interpace Diagnostics Group announced today that it has executed a new agreement with Laboratory Corporation of America that will expand the network of cytology providers in support of its thyroid molecular business unit.

Under the new agreement, physicians will be able to order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis. In the event of an indeterminate result, Interpace will perform its molecular test.